TY - JOUR
T1 - The Effect of a Hydrolyzed Polysaccharide Dietary Supplement on Biomarkers in Adults with Nonalcoholic Fatty Liver Disease
AU - Lewis, John E.
AU - Atlas, Steven E.
AU - Higuera, Oscar L.
AU - Fiallo, Andrea
AU - Rasul, Ammar
AU - Farooqi, Ashar
AU - Kromo, Olga
AU - Lantigua, Laura A.
AU - Tiozzo, Eduard
AU - Woolger, Judi M.
AU - Goldberg, Sharon
AU - Mendez, Armando
AU - Rodriguez, Allan E.
AU - Konefal, Janet
N1 - Funding Information:
The authors are thankful to all of the volunteers who participated in this study. Daiwa Health Development participated in the design of the protocol for the study. This work was supported by a gift from Daiwa Health Development. The study was also supported by Miami Clinical and Translational Science Institute from the National Center for Advancing Translational Sciences and the National Institute on Minority Health and Health Disparities [Grant no. 1UL1TR000460].
Publisher Copyright:
© 2018 John E. Lewis et al.
PY - 2018
Y1 - 2018
N2 - The primary objective of the study was to evaluate the effect of a hydrolyzed polysaccharide, Rice Bran Arabinoxylan Compound (RBAC), on biomarkers in adults with nonalcoholic fatty liver disease (NAFLD). A 90-day randomized double-blind placebo-controlled trial examined the effect of RBAC on complete blood count, liver enzymes, lipids, oxidative stress markers, cytokines, and growth factors. Twenty-three adults with NAFLD were enrolled and randomly assigned to one of the two study conditions (n=12 RBAC and n=11 placebo) and consumed 1 gram/day of either compound for 90 days. Subjects were assessed at baseline and 45 and 90 days. No adverse effects were reported. Alkaline phosphatase significantly decreased (-3.1%; SD = 19.9; F[1,19]=5.1, p=0.03) in the RBAC group compared to placebo. Percent monocytes (17.9%; SD = 18.3; F[1,19]=5.9, p=0.02) and percent eosinophils (30.6%; SD = 30.5; F[1,19]=12.3, p<0.01) increased in the RBAC group. IFN-γ (156%; SD = 131.8; F[1,19]=4.2, p=0.06) and IL-18 (29.1%; SD = 64; F[1,19]=5.3, p=0.03) increased in the RBAC group compared to placebo. Other improvements were noted for platelets, neutrophils, neutrophil-lymphocyte ratio, γ-glutamyl transferase, and 4-hydroxynonenal. RBAC had beneficial effects on several biomarkers that add to the known immunomodulatory activities of RBAC, which may be promising for people with NAFLD.
AB - The primary objective of the study was to evaluate the effect of a hydrolyzed polysaccharide, Rice Bran Arabinoxylan Compound (RBAC), on biomarkers in adults with nonalcoholic fatty liver disease (NAFLD). A 90-day randomized double-blind placebo-controlled trial examined the effect of RBAC on complete blood count, liver enzymes, lipids, oxidative stress markers, cytokines, and growth factors. Twenty-three adults with NAFLD were enrolled and randomly assigned to one of the two study conditions (n=12 RBAC and n=11 placebo) and consumed 1 gram/day of either compound for 90 days. Subjects were assessed at baseline and 45 and 90 days. No adverse effects were reported. Alkaline phosphatase significantly decreased (-3.1%; SD = 19.9; F[1,19]=5.1, p=0.03) in the RBAC group compared to placebo. Percent monocytes (17.9%; SD = 18.3; F[1,19]=5.9, p=0.02) and percent eosinophils (30.6%; SD = 30.5; F[1,19]=12.3, p<0.01) increased in the RBAC group. IFN-γ (156%; SD = 131.8; F[1,19]=4.2, p=0.06) and IL-18 (29.1%; SD = 64; F[1,19]=5.3, p=0.03) increased in the RBAC group compared to placebo. Other improvements were noted for platelets, neutrophils, neutrophil-lymphocyte ratio, γ-glutamyl transferase, and 4-hydroxynonenal. RBAC had beneficial effects on several biomarkers that add to the known immunomodulatory activities of RBAC, which may be promising for people with NAFLD.
UR - http://www.scopus.com/inward/record.url?scp=85048205472&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85048205472&partnerID=8YFLogxK
U2 - 10.1155/2018/1751583
DO - 10.1155/2018/1751583
M3 - Article
AN - SCOPUS:85048205472
VL - 2018
JO - Evidence-based Complementary and Alternative Medicine
JF - Evidence-based Complementary and Alternative Medicine
SN - 1741-427X
M1 - 1751583
ER -